AOU SS Antonio e Biagio e Cesare Arrigo di Alessandria - Protocolli Sindromi mieloprofliferative

Sindromi MIELOPROLIFERATIVE CRONICHE target: Essential Thrombocythemia

Contatti:  Monia Marchetti, Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

• MK3543-007 (pdf - 32 KB) :A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

• A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea. (pdf - 41 KB)

Sindromi MIELOPROLIFERATIVE CRONICHE target: MIELOFIBROSI

Contatti: Monia Marchetti Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

• A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor (pdf - 29 KB)

• GRN163LMYF3001.Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor (pdf - 33 KB)

• KRT-232-115. A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (pdf - 39 KB)

Sindromi MIELOPROLIFERATIVE CRONICHE target: Essential Thrombocythemia – Myelofibrosis

Contatti:  Monia Marchetti, Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

• MK3543-017. A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study (pdf - 28 KB)

Sindromi MIELOPROLIFERATIVE CRONICHE target: Polycythemia Vera

Contatti:  Monia Marchetti, Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

• ROPEG-PV. Observational study on the use of ropeginterferon alfa-2b in polycythemia vera (pdf - 25 KB)

• SLN124-004 Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (pdf - 29 KB)